Ukrainian Journal of Veterinary Sciences

The article presents the results of our own research on the therapeutic efficacy of using the medicinal product Ceftioclin while treating acute purulent-catarrhal mastitis in cows. The analysis of the distribution of mastitis in the experimental farm showed that the incidence of mastitis in cows was 39.0% from the total number of examined cows. At the same time, the clinical form of mastitis was diagnosed in 13.0% of animals. It should be noted that among the clinical forms the purulent-catarrhal mastitis was diagnosed in 39.7% of cows. It was established that with the complex use of Ceftioclin and Fos-Bevit while treating cows which are patient with acute purulent-catarrhal mastitis, the disappearance of clinical signs of mastitis and changes in the secretion of the mammary gland occurred on average in 4.1 ± 0.2 days. A negative reaction in a laboratory study of secretion from the mammary gland of cows with reagent Profilac Reagent N was noted on average in 5.0 ± 0.3 days from the start of treatment which is 1.9 days less than monotherapy

cows, purulent-catarral mastitis, Ceftioclin, Fos-Bevit